{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:31:37Z","timestamp":1793291497298,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T00:00:00Z","timestamp":1559606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T00:00:00Z","timestamp":1559606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013220","name":"Ultragenyx Pharmaceutical","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013220","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00223-019-00568-3","type":"journal-article","created":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T09:05:46Z","timestamp":1559639146000},"page":"271-284","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":157,"title":["Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period"],"prefix":"10.1007","volume":"105","author":[{"given":"Anthony A.","family":"Portale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas O.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Briot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae II","family":"Cheong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Cohen-Solal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Crowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Jan De Beur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Eastell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Imanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik A.","family":"Imel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Ing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Javaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kamenicky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Keen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuo","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Lachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzana","family":"Perwad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pisit","family":"Pitukcheewanont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart H.","family":"Ralston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Wook","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Theodore-Oklota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Mealiffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"San Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Insogna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,4]]},"reference":[{"key":"568_CR1","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/ng1095-130","volume":"11","author":"The HYP Consortium","year":"1995","unstructured":"The HYP Consortium (1995) A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 11:130\u2013136. \n                    https:\/\/doi.org\/10.1038\/ng1095-130","journal-title":"Nat Genet"},{"key":"568_CR2","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1056\/NEJMoa020881","volume":"348","author":"KB Jonsson","year":"2003","unstructured":"Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656\u20131663. \n                    https:\/\/doi.org\/10.1056\/nejmoa020881","journal-title":"N Engl J Med"},{"key":"568_CR3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1359\/JBMR.0301264","volume":"19","author":"T Shimada","year":"2004","unstructured":"Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429\u2013435. \n                    https:\/\/doi.org\/10.1359\/jbmr.0301264","journal-title":"J Bone Miner Res"},{"key":"568_CR4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1148\/radiology.171.2.2539609","volume":"171","author":"DC Hardy","year":"1989","unstructured":"Hardy DC, Murphy WA, Siegel BA, Reid IR, Whyte MP (1989) X-linked hypophosphatemia in adults: prevalence of skeletal radiographic and scintigraphic features. Radiology 171:403\u2013414. \n                    https:\/\/doi.org\/10.1148\/radiology.171.2.2539609","journal-title":"Radiology"},{"key":"568_CR5","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s10545-018-0147-6","volume":"41","author":"D Chesher","year":"2018","unstructured":"Chesher D, Oddy M, Darbar U, Sayal P, Casey A, Ryan A, Sechi A, Simister C, Waters A, Wedatilake Y, Lachmann RH, Murphy E (2018) Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations. J Inherit Metab Dis 41:865\u2013876. \n                    https:\/\/doi.org\/10.1007\/s10545-018-0147-6","journal-title":"J Inherit Metab Dis"},{"key":"568_CR6","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1530\/EC-13-0103","volume":"3","author":"A Linglart","year":"2014","unstructured":"Linglart A, Biosse-Duplan M, Briot K, Chaussain C, Esterle L, Guillaume-Czitrom S, Kamenicky P, Nevoux J, Prie D, Rothenbuhler A, Wicart P, Harvengt P (2014) Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect 3:R13\u201330. \n                    https:\/\/doi.org\/10.1530\/ec-13-0103","journal-title":"Endocr Connect"},{"key":"568_CR7","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1210\/jcem.75.6.1464657","volume":"75","author":"SA Rivkees","year":"1992","unstructured":"Rivkees SA, el-Hajj-Fuleihan G, Brown EM, Crawford JD (1992) Tertiary hyperparathyroidism during high phosphate therapy of familial hypophosphatemic rickets. J Clin Endocrinol Metab 75:1514\u20131518. \n                    https:\/\/doi.org\/10.1210\/jcem.75.6.1464657","journal-title":"J Clin Endocrinol Metab"},{"key":"568_CR8","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1056\/NEJM199112263252604","volume":"325","author":"CF Verge","year":"1991","unstructured":"Verge CF, Lam A, Simpson JM, Cowell CT, Howard NJ, Silink M (1991) Effects of therapy in X-linked hypophosphatemic rickets. N Engl J Med 325:1843\u20131848. \n                    https:\/\/doi.org\/10.1056\/nejm199112263252604","journal-title":"N Engl J Med"},{"key":"568_CR9","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/BF00860736","volume":"9","author":"A Taylor","year":"1995","unstructured":"Taylor A, Sherman NH, Norman ME (1995) Nephrocalcinosis in X-linked hypophosphatemia: effect of treatment versus disease. Pediatr Nephrol 9:173\u2013175","journal-title":"Pediatr Nephrol"},{"key":"568_CR10","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1172\/JCI72829","volume":"124","author":"TO Carpenter","year":"2014","unstructured":"Carpenter TO, Imel EA, Ruppe MD, Weber TJ, Klausner MA, Wooddell MM, Kawakami T, Ito T, Zhang X, Humphrey J, Insogna KL, Peacock M (2014) Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Investig 124:1587\u20131597. \n                    https:\/\/doi.org\/10.1172\/jci72829","journal-title":"J Clin Investig"},{"key":"568_CR11","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1210\/jc.2015-1551","volume":"100","author":"EA Imel","year":"2015","unstructured":"Imel EA, Zhang X, Ruppe MD, Weber TJ, Klausner MA, Ito T, Vergeire M, Humphrey JS, Glorieux FH, Portale AA, Insogna K, Peacock M, Carpenter TO (2015) Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23. J Clin Endocrinol Metab 100:2565\u20132573. \n                    https:\/\/doi.org\/10.1210\/jc.2015-1551","journal-title":"J Clin Endocrinol Metab"},{"key":"568_CR12","unstructured":"Ruppe M, Peacock M, Weber T, Portale A, Insogna K, Imel E, Luca D, Skrinar A, Mealiffe M, San Martin J, Carpenter T (2016) Clinical and radiographic characteristics of adult X-linked hypophosphatemia (XLH) in a cohort of patients treated with KRN23, an antibody to FGF23. In: Presented at: ASBMR 2016 annual meeting, 16\u201319 September 2016, Atlanta, Georgia Presentation, #MO0319"},{"key":"568_CR13","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/jbmr.3475","volume":"33","author":"KL Insogna","year":"2018","unstructured":"Insogna KL, Briot K, Imel EA, Kamenicky P, Ruppe MD, Portale AA, Weber T, Pitukcheewanont P, Cheong HI, Jan de Beur S, Imanishi Y, Ito N, Lachmann RH, Tanaka H, Perwad F, Zhang L, Chen CY, Theodore-Oklota C, Mealiffe M, San Martin J, Carpenter TO (2018) A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: Week 24 primary analysis. J Bone Miner Res 33:1383\u20131393. \n                    https:\/\/doi.org\/10.1002\/jbmr.3475","journal-title":"J Bone Miner Res"},{"key":"568_CR14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17:405\u2013424. \n                    https:\/\/doi.org\/10.1038\/gim.2015.30","journal-title":"Genet Med"},{"key":"568_CR15","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD EPI (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604\u2013612","journal-title":"Ann Intern Med"},{"key":"568_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/0304-3959(83)90143-4","volume":"17","author":"RL Daut","year":"1983","unstructured":"Daut RL, Cleeland CS, Flanery RC (1983) Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 17:197\u2013210","journal-title":"Pain"},{"key":"568_CR17","unstructured":"Bellamy N (2012) WOMAC osteoarthritis index user guide. Version X. Brisbane"},{"key":"568_CR18","doi-asserted-by":"publisher","unstructured":"ATS statement: guidelines for the six-minute walk test (2002). Am J Respir Crit Care Med 166:111\u2013117. \n                    https:\/\/doi.org\/10.1164\/ajrccm.166.1.at1102","DOI":"10.1164\/ajrccm.166.1.at1102"},{"key":"568_CR19","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.2214\/ajr.146.6.1253","volume":"146","author":"H Patriquin","year":"1986","unstructured":"Patriquin H, Robitaille P (1986) Renal calcium deposition in children: sonographic demonstration of the Anderson\u2013Carr progression. Am J Roentgenol 146:1253\u20131256. \n                    https:\/\/doi.org\/10.2214\/ajr.146.6.1253","journal-title":"Am J Roentgenol"},{"key":"568_CR20","first-page":"131","volume":"29","author":"F Angst","year":"2002","unstructured":"Angst F, Aeschlimann A, Michel BA, Stucki G (2002) Minimal clinically important rehabilitation effects in patients with osteoarthritis of the lower extremities. J Rheumatol 29:131\u2013138","journal-title":"J Rheumatol"},{"key":"568_CR21","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.340","volume":"26","author":"TO Carpenter","year":"2011","unstructured":"Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL (2011) A clinician\u2019s guide to X-linked hypophosphatemia. J Bone Miner Res 26:1381\u20131388. \n                    https:\/\/doi.org\/10.1002\/jbmr.340","journal-title":"J Bone Miner Res"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-019-00568-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00223-019-00568-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-019-00568-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T23:21:54Z","timestamp":1591140114000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00223-019-00568-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,4]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["568"],"URL":"https:\/\/doi.org\/10.1007\/s00223-019-00568-3","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,4]]},"assertion":[{"value":"6 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The institution that employs AAP and FP received research grants from Ultragenyx for this and other studies. AAP reports advisory board membership and lectures for Ultragenyx. TOC reports research grants from Ultragenyx and consultancy for Clementia, Inozyme, Pharmacosmos, Kirin, and Lakeside. MLB reports Honoraria from Amgen, Bruno Farmaceutici, and Kyowa Kirin, Grants and\/or Speaker Fees from Abiogen, Alexion, Amgen, Bruno Farmaceutici, Eli Lilly, Kyowa Kirin, MSD, NPS, Servier, Shire, and SPA, and consultancy for Alexion, Bruno Farmaceutici, Kyowa Kirin, Servier, and Shire. KB reports Personal Fees from Kyowa Kirin, UCB, Amgen, and Lilly. RC reports Grants and Non-financial Support from Ultragenyx. SJdB reports Research Grants, Advisory Board Membership, and Consultancy for Ultragenyx. RE reports Grants and Personal Fees from Amgen and Alexion, Grants from Department of Health, AstraZeneca, ARUK\/MRC Centre for Excellence in Musculoskeletal Ageing Research, National Institute for Health Research, MRC\/AZ Mechanisms of Diseases Call, and MRC, Grants, Personal Fees, and Non-financial Support from Immunodiagnostic Systems, Grants and other from National Osteoporosis Society, Grants, Personal Fees, and other from Roche, Personal Fees and other from Eli Lilly, other from European Calcified Tissue Society, IOF CSA, IBMS, and ASBMR, and Personal Fees from D-STAR and GSK Nutrition. YI reports Grants from Kyowa Hakko Kirin Co., Ltd. EAI reports Grants and Advisory Board Membership for Ultragenyx Pharmaceutical, Inc. SI reports Research Grants from Ultragenyx. NI and TK report research Grants from Kyowa Hakko Kirin. MJ reports Research Grants and Advisory Board Membership for Kyowa Kirin. PK reports research grants from Ultragenyx. RK reports Research Grants and Speaking Fees from Kyowa Kirin. FP reports Advisory Board Membership and Lectures for Ultragenyx. PP reports Research Grants from Amgen, Ultragenyx, and Shire, and employment by Ascendis Pharma, Inc. SHR reports support from Ultragenyx, Kyowa Kirin, Lilly, and Amgen\/UCB for enrolling patients into clinical trials, and non-financial support from Eli Lilly. YT reports Personal Fees from Kyowa Hakko Kirin Co. Ltd., and Grants and Personal Fees from Chugai Pharmaceutical Co. Ltd. and Teijin Pharma Ltd. TJW reports Research Support, Travel Fees, and Honoraria from Ultragenyx Pharmaceutical, Inc. LZ, CTO, MM, and JSM were employees and stockholders of Ultragenyx Pharmaceutical, Inc. during the study. JSM has a Patent Pending that is jointly owned by Ultragenyx Pharmaceutical, Inc. KI reports Research Grants and Advisory Board Membership for Ultragenyx. HIC, MCS, RL, HT, and HWY have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in human participants were in accordance with the Ethical Standards of the Institutional and\/or National Research Committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"Informed consent was obtained from all study participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}